White Paper

Phenotypic Drug Discovery with High Content Screening


Today's drug discovery strategies require candidate compounds to fail early and cheaply in the discovery stage, rather than late and expensively in the clinical phase. Testing compounds early in physiologically relevant model systems and leveraging rich information from image-based screens are ways of focusing on those compounds that give rise to the right phenotypic changes without undesirable effects on the system.


  1. Why you should consider phenotypic vs. target based drug discovery strategies
  2. Challenges you should be aware of for phenotypic assays
  3. How to maximize the return on your phenotypic assays